metformin has been researched along with Aura in 9 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Preclinical and clinical evidence involving metformin's role in epilepsy and special conditions like tuberous sclerosis have been reviewed in this paper." | 9.22 | A review on role of metformin as a potential drug for epilepsy treatment and modulation of epileptogenesis. ( Sarangi, SC; Singh, R; Singh, S; Tripathi, M, 2022) |
| "The present study was designed to examine the possible neuroprotective and antiepileptic effects of metformin (Metf) in a rat model of pentylenetetrazole (PTZ)-induced epilepsy and its possible underlying mechanisms." | 7.91 | Effects of metformin on apoptosis and α-synuclein in a rat model of pentylenetetrazole-induced epilepsy. ( Abbas, KM; Abulseoud, OA; Ali, AN; El-Mesery, M; El-Shafey, M; Eldosoky, M; Hussein, AM, 2019) |
| "Metformin is a drug in the family of biguanide compounds that is widely used in the treatment of type 2 diabetes (T2D)." | 6.72 | Beneficial Effects of Metformin on the Central Nervous System, with a Focus on Epilepsy and Lafora Disease. ( Sánchez, MP; Sanz, P; Serratosa, JM, 2021) |
| "Epilepsy is a neurological disorder characterized by an enduring predisposition to generate and aggravate epileptic seizures affecting around 1% of global population making it a serious health concern." | 6.61 | Envisioning the neuroprotective effect of Metformin in experimental epilepsy: A portrait of molecular crosstalk. ( H S, N; K L, K; Paudel, YN, 2019) |
| "Preclinical and clinical evidence involving metformin's role in epilepsy and special conditions like tuberous sclerosis have been reviewed in this paper." | 5.22 | A review on role of metformin as a potential drug for epilepsy treatment and modulation of epileptogenesis. ( Sarangi, SC; Singh, R; Singh, S; Tripathi, M, 2022) |
| "We searched PubMed, SCOPUS, Sciences Direct, and grey literature in order to explore articles published in English from January 2010 to November 2018, using key terms "epilepsy," "seizure," "metformin," "oral hypoglycemic agents," and "oral antidiabetic drugs"." | 5.01 | The Effect of Metformin in Experimentally Induced Animal Models of Epileptic Seizure. ( Gebre, AK; Surur, A; Wondafrash, DZ; Yimer, EM, 2019) |
| "The present study was designed to examine the possible neuroprotective and antiepileptic effects of metformin (Metf) in a rat model of pentylenetetrazole (PTZ)-induced epilepsy and its possible underlying mechanisms." | 3.91 | Effects of metformin on apoptosis and α-synuclein in a rat model of pentylenetetrazole-induced epilepsy. ( Abbas, KM; Abulseoud, OA; Ali, AN; El-Mesery, M; El-Shafey, M; Eldosoky, M; Hussein, AM, 2019) |
| "Metformin is a drug in the family of biguanide compounds that is widely used in the treatment of type 2 diabetes (T2D)." | 2.72 | Beneficial Effects of Metformin on the Central Nervous System, with a Focus on Epilepsy and Lafora Disease. ( Sánchez, MP; Sanz, P; Serratosa, JM, 2021) |
| "Epilepsy is a neurological disorder characterized by an enduring predisposition to generate and aggravate epileptic seizures affecting around 1% of global population making it a serious health concern." | 2.61 | Envisioning the neuroprotective effect of Metformin in experimental epilepsy: A portrait of molecular crosstalk. ( H S, N; K L, K; Paudel, YN, 2019) |
| "CA6 and CA12 (p." | 1.91 | Anticonvulsant Profile of Selected Medium-Chain Fatty Acids (MCFAs) Co-Administered with Metformin in Mice in Acute and Chronic Treatment. ( Nieoczym, D; Pieróg, M; Samorek-Pieróg, M; Socała, K; Wlaź, P; Wyska, E, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 5 (55.56) | 2.80 |
| Authors | Studies |
|---|---|
| Singh, R | 1 |
| Sarangi, SC | 1 |
| Singh, S | 1 |
| Tripathi, M | 1 |
| Jurca, CM | 1 |
| Kozma, K | 1 |
| Petchesi, CD | 1 |
| Zaha, DC | 1 |
| Magyar, I | 1 |
| Munteanu, M | 1 |
| Faur, L | 1 |
| Jurca, A | 1 |
| Bembea, D | 1 |
| Severin, E | 1 |
| Jurca, AD | 1 |
| Pieróg, M | 1 |
| Socała, K | 1 |
| Nieoczym, D | 1 |
| Wyska, E | 1 |
| Samorek-Pieróg, M | 1 |
| Wlaź, P | 1 |
| Kopel, J | 1 |
| Grooms, A | 1 |
| Ganapathy, V | 1 |
| Clothier, J | 1 |
| Sanz, P | 1 |
| Serratosa, JM | 1 |
| Sánchez, MP | 1 |
| Rubio Osornio, MDC | 1 |
| Custodio Ramírez, V | 1 |
| Calderón Gámez, D | 1 |
| Paz Tres, C | 1 |
| Carvajal Aguilera, KG | 1 |
| Phillips Farfán, BV | 1 |
| Hussein, AM | 1 |
| Eldosoky, M | 1 |
| El-Shafey, M | 1 |
| El-Mesery, M | 1 |
| Ali, AN | 1 |
| Abbas, KM | 1 |
| Abulseoud, OA | 1 |
| Yimer, EM | 1 |
| Surur, A | 1 |
| Wondafrash, DZ | 1 |
| Gebre, AK | 1 |
| H S, N | 1 |
| Paudel, YN | 1 |
| K L, K | 1 |
5 reviews available for metformin and Aura
| Article | Year |
|---|---|
A review on role of metformin as a potential drug for epilepsy treatment and modulation of epileptogenesis.
Topics: AMP-Activated Protein Kinases; Anticonvulsants; Epilepsy; Humans; Metformin; TOR Serine-Threonine Ki | 2022 |
Tuberous Sclerosis, Type II Diabetes Mellitus and the PI3K/AKT/mTOR Signaling Pathways-Case Report and Literature Review.
Topics: Adolescent; Adult; Diabetes Mellitus, Type 2; Epilepsy; Female; Humans; Infant; Metformin; Phosphati | 2023 |
Beneficial Effects of Metformin on the Central Nervous System, with a Focus on Epilepsy and Lafora Disease.
Topics: Animals; Central Nervous System; Diabetes Mellitus, Type 2; Disease Models, Animal; Epilepsy; Humans | 2021 |
The Effect of Metformin in Experimentally Induced Animal Models of Epileptic Seizure.
Topics: Animals; Anticonvulsants; Behavior; Epilepsy; Humans; Metformin; Models, Animal; Seizures | 2019 |
Envisioning the neuroprotective effect of Metformin in experimental epilepsy: A portrait of molecular crosstalk.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Epilepsy; Hypoglycemic Agents; Metformin | 2019 |
4 other studies available for metformin and Aura
| Article | Year |
|---|---|
Anticonvulsant Profile of Selected Medium-Chain Fatty Acids (MCFAs) Co-Administered with Metformin in Mice in Acute and Chronic Treatment.
Topics: AMP-Activated Protein Kinases; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relat | 2023 |
Metformin, valproic acid, and starvation induce seizures in a patient with partial SLC13A5 deficiency: a case of pharmaco-synergistic heterozygosity.
Topics: Adult; Amino Acid Substitution; Ammonia; Animals; Anticonvulsants; Autistic Disorder; Bipolar Disord | 2021 |
Metformin Plus Caloric Restriction Show Anti-epileptic Effects Mediated by mTOR Pathway Inhibition.
Topics: AMP-Activated Protein Kinases; Animals; Anticonvulsants; Caloric Restriction; Combined Modality Ther | 2018 |
Effects of metformin on apoptosis and α-synuclein in a rat model of pentylenetetrazole-induced epilepsy.
Topics: alpha-Synuclein; Animals; Apoptosis; Convulsants; Epilepsy; Male; Metformin; Pentylenetetrazole; Rat | 2019 |